Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of AQUA07 Monotherapy and Combination Therapy in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

NCT07617337 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT07617337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07617337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of AQUA07 Monotherapy and Combination Therapy in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1
Overall status
Recruiting
Start date
July 24, 2026
Completion date
August 31, 2030
Enrollment
102 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

alk positive non-small cell lung cancer